DiscoverMedscape InDiscussion: Multiple SclerosisS2 Episode 4: Should Platform Therapies Remain First-Line in MS?
S2 Episode 4: Should Platform Therapies Remain First-Line in MS?

S2 Episode 4: Should Platform Therapies Remain First-Line in MS?

Update: 2025-09-18
Share

Description

Drs Anne Cross and Scott Newsome discuss new horizons in MS treatment strategies, including the TREAT-MS trial and shared decision-making for optimal patient care.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002606. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. 

Resources

Multiple Sclerosis https://emedicine.medscape.com/article/1146199-overview

Interferon Beta and Glatiramer Acetate Therapy https://pubmed.ncbi.nlm.nih.gov/23264098/

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS) https://www.clinicaltrials.gov/study/NCT03500328

Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020 https://pubmed.ncbi.nlm.nih.gov/37428482/

What We Learned From the History of Multiple Sclerosis Measurement: Expanded Disability Status Scale https://pubmed.ncbi.nlm.nih.gov/30692861/

The Multiple Sclerosis Functional Composite Measure (MSFC): An Integrated Approach to MS Clinical Outcome Assessment. National MS Society Clinical Outcomes Assessment Task Force https://pubmed.ncbi.nlm.nih.gov/10467383/

Long-term Efficacy and Safety of Alemtuzumab in Participants With Highly Active MS: TOPAZ Clinical Trial and Interim Analysis of TREAT-MS Real-World Study https://pubmed.ncbi.nlm.nih.gov/39935588/

Imaging Outcome Measures for Progressive Multiple Sclerosis Trials https://pubmed.ncbi.nlm.nih.gov/29041865/

Current Use of Fluid Biomarkers as Outcome Measures in Multiple Sclerosis (MS): A Review of Ongoing Pharmacological Clinical Trials https://pubmed.ncbi.nlm.nih.gov/38117403/

Patient-reported Disability Progression Outcomes Among Patients With Multiple Sclerosis: Results of an Outcomes-Based Agreement https://pubmed.ncbi.nlm.nih.gov/39471272/

Insights for Healthcare Providers on Shared Decision-making in Multiple Sclerosis: A Narrative Review https://pubmed.ncbi.nlm.nih.gov/38180727/

Practice Guideline Update Summary: Vaccine-Preventable Infections and Immunization in Multiple Sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology https://pubmed.ncbi.nlm.nih.gov/31462584/

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

S2 Episode 4: Should Platform Therapies Remain First-Line in MS?

S2 Episode 4: Should Platform Therapies Remain First-Line in MS?